Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2012

View Archived Issues

Small peptide ALK-3 agonist demonstrates regenerative potential in kidney

New encapsulated stem cell therapy induces cell death in gliomas

Notch mRNA signature biomarker monitors effects of PS-1-selective GSI

New JAK modulators described

Bayer Schering Pharma develops new vasopressin receptor ligands

New potential anticancer drugs developed in China

Novel RAR-related orphan receptor modulators presented

Novel potential hepatitis therapies reported

Actelion divulges novel orexin receptor antagonists

Phase II BTA-798 trial meets primary endpoint

MorphoSys receives milestone payment from Novartis

Final phase III Heplisav data are encouraging

FDA approves line extension for etravirine

Search for novel triple reuptake inhibitors yields ALB-109780

Lorus Therapeutics presents preclinical data on small-molecule antimicrobial

NGM and Daiichi Sankyo to collaborate on novel diabetes therapies

BioSeek and Merck Serono extend BioMAP collaboration

Chelsea Therapeutics receives complete response letter regarding Northera

Allergan seeks approval for line extension of Botox

Protox advances PRX-302 trial

Treatment begins in first-in-human CO-1686 study

DSMB recommends continuation of Menerba study

Trillium Therapeutics doses first patient in phase I trial of TTI-1612

Ultragenyx obtains orphan drug designations in Europe for two lead products

Gruenenthal reports new potassium channel modulators

JDRF and iCo Therapeutics join to support iDEAL trial

Depomed receives remaining license fee payment in Acuform collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...